What’s changing, why it matters, and what covered entities should expect before 2026
1. What’s Changing — A Snapshot
On October 30, 2025, the Health Resources and Services Administration (HRSA) approved 340B rebate models for nine drugs under its controversial 340B Rebate Pilot Program, launching January 1, 2026.
The pilot allows manufacturers of drugs included in the first round of Medicare price negotiations to replace the traditional point-of-sale 340B discount with a rebate-based structure if approved by HRSA.
Approved Drugs:
- Bristol Myers Squibb – Eliquis
- Amgen – Enbrel
- AstraZeneca – Farxiga
- Pharmacyclics (AbbVie) – Imbruvica
- Merck – Januvia
- Novo Nordisk – Fiasp
- Boehringer Ingelheim – Jardiance
- Johnson & Johnson – Stelara and Xarelto
Pending: Novartis’ Entresto is the only drug from the original ten not yet approved, though the manufacturer has indicated plans to participate once HRSA-requested updates are made.
All approved rebate models will apply to all covered entity types and will operate through Beacon Channel Management, a platform owned by Second Sight Solutions, the same parent company that operates the 340B ESP claims clearinghouse.
Manufacturers must share their full rebate model implementation plans with covered entities by November 2, 2025, providing the 60-day notice required ahead of the pilot’s launch.
2. How the Rebate Model Works
Under the pilot, covered entities will purchase the affected drugs at Wholesale Acquisition Cost (WAC) and later submit claims data to receive a rebate equivalent to the 340B discount.
While designed to increase “transparency and accountability,” the model shifts the financial burden and data workload onto safety-net providers. HRSA also added new medical claims data elements, expanding the types of information entities must provide to qualify for rebates.
Key Changes from Earlier Drafts
- Expanded Data Reporting: Covered entities must now include additional medical claims fields.
- Universal Coverage: All entity types (hospitals, CHCs, clinics) are included — reversing HRSA’s earlier suggestion that manufacturers could limit participation.
- Beacon Administration: All transactions and data will flow through the Beacon platform, which providers have described as complex and time-consuming, citing past challenges with 340B ESP.
3. Provider Concerns
Provider organizations immediately voiced concern over the pilot’s operational and financial implications.
- Administrative Burden: The new reporting requirements add complexity, especially for smaller or rural entities with limited staff and technology infrastructure.
- Cash Flow Risk: Entities must front WAC pricing and wait for rebate payments, a significant shift from the upfront 340B discount model.
- Program Intent: Groups like America’s Essential Hospitals (AEH), NACHC, and Advocates for Community Health (ACH) argue the rebate structure undermines the program’s goal of helping safety-net providers “stretch scarce resources to serve more patients.”
4. Legal & Policy Context
HRSA’s approvals arrive amid ongoing litigation between the agency and several drugmakers — including Novartis, J&J, BMS, Sanofi, and Lilly — over whether manufacturers can independently implement rebate models without HRSA’s preapproval.
Two federal courts sided with HRSA earlier this year, confirming its authority to oversee and approve rebate programs. The consolidated appeal is scheduled for oral argument before the D.C. Circuit Court of Appeals on November 17, 2025.
Meanwhile, policymakers on both sides of the aisle continue to scrutinize the 340B program. A bipartisan group of 163 House members previously urged HRSA to abandon the rebate pilot entirely, citing risks to patient access and provider sustainability.
5. Impact & Implications
Covered Entities:
- Expect new data submission and reconciliation requirements under Beacon.
- Prepare for cash flow delays due to upfront purchasing.
- Review HRSA and manufacturer implementation plans carefully — all must be distributed by Nov. 2, 2025.
- Engage compliance and revenue cycle teams early to align processes.
Patients:
- Access may be affected if providers cannot absorb upfront costs.
- Health centers and small hospitals face the greatest risk of drug discontinuation.
Policy & Oversight:
- The pilot will test HRSA’s capacity to act as a neutral “referee” when disputes arise.
- Its results could influence future Congressional action on 340B transparency and reform.
6. What You Should Do
- Monitor communications from HRSA and participating manufacturers about implementation timelines.
- Evaluate financial readiness for WAC purchases and delayed rebate payments.
- Assess data infrastructure — ensure your team or TPA can meet expanded claims reporting requirements.
- Engage in advocacy through your state association or 340B network to ensure provider perspectives are heard.
Bottom Line
The 340B rebate pilot marks the most significant structural shift in the program’s history. While drugmakers see a move toward accountability, providers fear new administrative burdens and cash flow risks that could weaken safety-net care.
How HRSA enforces compliance and mediates disputes over the next year will determine whether this model strengthens transparency or undermines the 340B program’s mission to support vulnerable patients.
ACI is prepared to handle the additional workload with a workflow that will ease the burden from the Covered Entities’ shoulders. This will include the submission of claims, the tracking of the rebate payments, and working closely with Beacon regarding any rejected rebates. In this time of uncertainty, ACI is here to support those who are doing the work to aid rural communities to expand scarce resources.
For more information regarding the 340B Rebate Model, visit HRSA’s official 340B Rebate Pilot Program page.